Christine Ibilibor, MD, discusses 6 noteworthy abstracts from the 2022 Genitourinary Cancers Symposium.
In this video, Urology Times® Editorial Council member Christine Ibilbor, MD, discusses abstracts on metastatic urothelial carcinoma, renal cell carcinoma, and rare cancers that will be presented at the 2022 Genitourinary Cancers Symposium. Ibilibor is an assistant professor of urology at the University of Virginia in Charlottesville.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.